Physician profile
Thomas Singer
NPI 1003142084
$1,031.16
in general payments reported to CMS, 2019-2025
14 companies · $20.09 in 2025
The $20.09 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $147 · 2020: $22.63 · 2021: $36.79 · 2022: $343 · 2023: $352 · 2024: $109 · 2025: $20.09.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $481.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $481.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hill Dermaceuticals, INC. | $318.85 | 2023 | Tolak |
| Medtronic, INC. | $175.00 | 2022 | |
| Abbvie INC. | $147.29 | 2019 | |
| Ucb, INC. | $127.94 | 2022 | |
| Novartis Pharmaceuticals Corporation | $46.60 | 2020-2022 | |
| Pfizer INC. | $37.83 | 2021-2023 | |
| Amgen INC. | $35.07 | 2022-2024 | Otezla |
| Convatec INC. | $34.07 | 2024 | |
| Sun Pharmaceutical Industries INC. | $23.61 | 2024 | |
| Organogenesis INC. | $20.09 | 2025 | Puraply Wound Matrix |
| Galderma Laboratories, L.P. | $18.44 | 2021 | |
| Verrica Pharmaceuticals INC. | $17.52 | 2024 | Ycanth |
| Janssen Biotech, INC. | $14.93 | 2024 | Simponi Aria, Simponi, Stelara |
| Strata Skin Sciences, INC. | $13.92 | 2023 | Xtrac |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Singer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.